This study sought to analyze outcomes in patients with moderate-severe tricuspid regurgitation (TR) undergoing transcatheter aortic valve replacement (TAVR). The consequences of uncorrected significant TR in patients undergoing TAVR remain undefined.
Methods
Between 2009 and 2014, 369 patients underwent TAVR at our institution, and 58 of these had baseline moderate-severe TR. Preoperative, 30-day, and 1-year transthoracic echocardiograms were analyzed. Predictors of persistent TR at 30 days and survival were assessed.
Results
Fifty-eight patients with baseline moderate-severe TR underwent TAVR. Transcatheter aortic valve replacement resulted in significant reductions in pulmonary artery pressures and TR severity (100% vs 64%; P < 0.001) at 30 days. This was sustained at 1 year and was associated with significant improvements in stroke volume index and New York Heart Association functional class. No changes in right ventricular function or size were noted. The only independent predictor of persistent moderate-severe TR at 30 days was preoperative atrial fibrillation [AF; odds ratio (OR), 4.56; 95% confidence interval, 1.1–18.3; P = 0.033]. Independent predictors of overall long-term survival included AF (OR, 0.41; P = 0.001) and chronic lung disease (OR, 0.47; P = 0.011), but not baseline moderate-severe TR. In patients with baseline moderate-severe TR, persistent moderate-severe TR at 30 days was associated with worsened overall survival (log-rank P = 0.02).
Conclusions
Baseline moderate-severe TR is not uncommon in patients undergoing TAVR, and frequently improves. However, the presence of AF suggests that that TR is likely to persist after TAVR and is also indicative of a poor long-term outcome. Whether redirecting such patients to surgery for concomitant tricuspid valve repair will further improve outcomes requires further study.
NishimuraR.A., OttoC.M., BonowR.O.American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol.2014; 63: 2438–2488.
2.
JeongD.S., SungK., KimW.S.Fate of functional tricuspid regurgitation in aortic stenosis after aortic valve replacement. J Thorac Cardiovasc Surg.2014; 148: 1328–1333.
3.
TaramassoM., MaisanoF., De BonisM.Prognostic impact and late evolution of untreated moderate (2/4+) functional tricuspid regurgitation in patients undergoing aortic valve replacement. J Card Surg.2016; 31: 9–14.
4.
DumontC., GalliE., OgerE.Pre- and postoperative tricuspid regurgitation in patients with severe symptomatic aortic stenosis: importance of preoperative tricuspid annulus diameter. Eur Heart J Cardiovasc Imaging.2018; 19: 319–328.
5.
KilicA., Saha-ChaudhuriP., RankinJ.S.Trends and outcomes of tricuspid valve surgery in North America: an analysis of more than 50,000 patients from the Society of Thoracic Surgeons database. Ann Thorac Surg.2013; 96: 1546–1552.
6.
SmithC.R., LeonM.B., MackM.J.PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med.2011; 364: 2187–2198.
7.
LeonM.B., SmithC.R., MackM.PARTNER Trial Investigators. Trans-catheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med.2010; 363: 1597–1607.
8.
PopmaJ.J., AdamsD.H., ReardonM.J.Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol.2014; 63: 1972–1981.
9.
AdamsD.H., PopmaJ.J., ReardonM.J.U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med.2014; 370: 1790–1798.
10.
ReardonM.J., Van MieghemN.M., PopmaJ.J.SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med.2017; 376: 1321–1331.
11.
LeonM.B., SmithC.R., MackM.J.Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med.2016; 374: 1609–1620.
12.
LindmanB.R., ManiarH.S., JaberW.A.Effect of tricuspid regurgitation and the right heart on survival after transcatheter aortic valve replacement: insights from the Placement of Aortic Transcatheter Valves II inoperable cohort. Circ Cardiovasc Interv.2015; 8.
13.
HutterA., BleizifferS., RichterV.Transcatheter aortic valve implantation in patients with concomitant mitral and tricuspid regurgitation. Ann Thorac Surg.2013; 95: 77–84.
14.
WilbringM., TugtekinS-M, RitzmannM.Transcatheter aortic valve implantation reduces grade of concomitant mitral and tricuspid valve regurgitation and pulmonary hypertension. Eur J Cardiothorac Surg.2014; 46: 818–824.
15.
SchwartzL.A., RozenbaumZ., GhantousE.Impact of right ventricular dysfunction and tricuspid regurgitation on outcomes in patients undergoing transcatheter aortic valve replacement. J Am Soc Echocardiogr. 2017; 30: 36–46.
16.
BarbantiM., BinderR.K., DvirD.Prevalence and impact of preoperative moderate/severe tricuspid regurgitation on patients undergoing transcatheter aortic valve replacement. Catheter Cardiovasc Interv.2015; 85: 677–684.
17.
DouglasP.S., WaughR.A., BloomfieldG.Implementation of echocardiography core laboratory best practices: a case study of the PARTNER I trial. J Am Soc Echocardiogr.2013; 26: 348–358.
18.
ZoghbiW.Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr.2003; 16: 777–802.
19.
RudskiL.G., LaiW.W., AfilaloJ.Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr.2010; 23: 685–713; quiz 786.
20.
DevereuxR.B., AlonsoD.R., LutasE.M.Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol.1986; 57: 450–458.
21.
ChangJ.D., ManningW.J., EbrilleE.Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol.2017; 69: 2331–2341.
22.
McCarthyP.M., BhudiaS.K., RajeswaranJ.Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg.2004; 127: 674–685.
23.
ChikweJ., ItagakiS., AnyanwuA.Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse. J Am Coll Cardiol.2015; 65: 1931–1938.
24.
SedaghatA., Al-RashidF., SinningJ.M.Outcome in TAVI patients with symptomatic aortic stenosis not fulfilling PARTNER study inclusion criteria. Catheter Cardiovasc Interv.2015; 86: 1097–1104.
25.
CortésC., Amat-SantosI.J., Nombela-FrancoL.Mitral regurgitation after transcatheter aortic valve replacement: prognosis, imaging predictors, and potential management. JACC Cardiovasc Interv.2016; 9: 1603–1614.
26.
VismaraR., GelpiG., PrabhuS.Transcatheter edge-to-edge treatment of functional tricuspid regurgitation in an ex vivo pulsatile heart model. J Am Coll Cardiol.2016; 68: 1024–1033.
27.
Campelo-ParadaF., PerlmanG., PhilipponF.First-in-man experience of a novel transcatheter repair system for treating severe tricuspid regurgitation. J Am Coll Cardiol.2015; 66: 2475–2483.
28.
SchoferJ., BijuklicK., TiburtiusC.First-in-human transcatheter tricuspid valve repair in a patient with severely regurgitant tricuspid valve. J Am Coll Cardiol.2015; 65: 1190–1195.
29.
Rodés-CabauJ., HahnR.T., LatibA.Transcatheter therapies for treating tricuspid regurgitation. J Am Coll Cardiol.2016; 67: 1829–1845.
30.
ItoS., PislaruS.V., SooW.M.Impact of right ventricular size and function on survival following transcatheter aortic valve replacement. Int J Cardiol.2016; 221: 269–274.
31.
KoifmanE., DidierR., PatelN.Impact of right ventricular function on outcome of severe aortic stenosis patients undergoing transcatheter aortic valve replacement. Am Heart J.2017; 184: 141–147.
32.
TangM., LiuX., LinC.Meta-analysis of outcomes and evolution of pulmonary hypertension before and after transcatheter aortic valve implantation. Am J Cardiol.2017; 119: 91–99.
33.
TestaL., LatibA., De CarloM.Persistence of severe pulmonary hypertension after transcatheter aortic valve replacement: incidence and prognostic impact. Circ Cardiovasc Interv.2016; 9: e003563.
34.
KammerlanderA.A., MarzlufB.A., GrafA.Right ventricular dysfunction, but not tricuspid regurgitation, is associated with outcome late after left heart valve procedure. J Am Coll Cardiol.2014; 64: 2633–2642.
35.
ChopardR., TeigerE., MeneveauN.Baseline characteristics and prognostic implications of pre-existing and new-onset atrial fibrillation after transcatheter aortic valve implantation: results from the FRANCE-2 registry. JACC Cardiovasc Interv.2015; 8: 1346–1355.
